Penbrook Management LLC Buys Shares of 5,500 Novartis AG (NVS)

Penbrook Management LLC bought a new position in Novartis AG (NYSE:NVS) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor bought 5,500 shares of the company’s stock, valued at approximately $462,000.

Several other large investors have also recently made changes to their positions in NVS. Garland Capital Management Inc. increased its position in Novartis by 1.0% during the 4th quarter. Garland Capital Management Inc. now owns 52,233 shares of the company’s stock valued at $4,385,000 after buying an additional 535 shares in the last quarter. Tradition Capital Management LLC increased its position in Novartis by 0.9% during the 4th quarter. Tradition Capital Management LLC now owns 69,381 shares of the company’s stock valued at $5,825,000 after buying an additional 652 shares in the last quarter. Commerce Bank increased its position in Novartis by 2.4% during the 4th quarter. Commerce Bank now owns 28,004 shares of the company’s stock valued at $2,352,000 after buying an additional 664 shares in the last quarter. West Oak Capital LLC increased its position in Novartis by 4.4% during the 4th quarter. West Oak Capital LLC now owns 15,860 shares of the company’s stock valued at $1,332,000 after buying an additional 665 shares in the last quarter. Finally, Lenox Wealth Management Inc. increased its position in Novartis by 6.9% during the 3rd quarter. Lenox Wealth Management Inc. now owns 10,585 shares of the company’s stock valued at $908,000 after buying an additional 683 shares in the last quarter. 10.76% of the stock is owned by hedge funds and other institutional investors.

How to Become a New Pot Stock Millionaire

A number of research analysts recently weighed in on NVS shares. Nord/LB reaffirmed a “neutral” rating on shares of Novartis in a research report on Tuesday, January 2nd. Bank of America lowered Novartis from a “neutral” rating to an “underperform” rating in a research report on Wednesday, December 6th. Zacks Investment Research lowered Novartis from a “hold” rating to a “sell” rating in a report on Tuesday, January 2nd. UBS reissued a “neutral” rating on shares of Novartis in a report on Monday, January 15th. Finally, JPMorgan Chase & Co. reissued a “neutral” rating on shares of Novartis in a report on Thursday, January 18th. Four investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and one has assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average target price of $87.51.

Shares of Novartis AG (NVS) opened at $79.74 on Friday. The company has a market capitalization of $187,899.34, a price-to-earnings ratio of 24.54, a price-to-earnings-growth ratio of 1.82 and a beta of 0.78. Novartis AG has a fifty-two week low of $72.67 and a fifty-two week high of $94.19. The company has a quick ratio of 0.91, a current ratio of 1.21 and a debt-to-equity ratio of 0.31.

Novartis (NYSE:NVS) last posted its earnings results on Wednesday, January 24th. The company reported $1.20 EPS for the quarter, topping the Zacks’ consensus estimate of $1.16 by $0.04. The business had revenue of $12.92 billion during the quarter, compared to analyst estimates of $12.65 billion. Novartis had a return on equity of 16.03% and a net margin of 15.69%. The company’s quarterly revenue was up 4.8% compared to the same quarter last year. During the same quarter last year, the company earned $1.14 EPS. sell-side analysts expect that Novartis AG will post 5.33 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “Penbrook Management LLC Buys Shares of 5,500 Novartis AG (NVS)” was reported by Ticker Report and is owned by of Ticker Report. If you are reading this piece on another publication, it was illegally copied and republished in violation of US & international trademark and copyright laws. The original version of this piece can be read at https://www.tickerreport.com/banking-finance/3293908/penbrook-management-llc-buys-shares-of-5500-novartis-ag-nvs.html.

Novartis Profile

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.

Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVS).

Institutional Ownership by Quarter for Novartis (NYSE:NVS)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Head-To-Head Review: Athene  and Genworth Financial
Head-To-Head Review: Athene and Genworth Financial
Head-To-Head Review: Engility  versus Hill International
Head-To-Head Review: Engility versus Hill International
Kellogg’s  and Post  Critical Review
Kellogg’s and Post Critical Review
Huron Consulting Group  Receives Average Recommendation of “Hold” from Analysts
Huron Consulting Group Receives Average Recommendation of “Hold” from Analysts
Viberate  Trading Up 16.8% Over Last Week
Viberate Trading Up 16.8% Over Last Week
GoldCoin Trading Up 61.8% This Week
GoldCoin Trading Up 61.8% This Week


© 2006-2018 Ticker Report. Google+.